Autobahn Therapeutics today announced that Kevin Finney, President and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference in New York on Tuesday, June 4, 2024.
SAN DIEGO--(BUSINESS WIRE)-- Autobahn Therapeutics a biotechnology company leveraging its brain-targeting chemistry platform, validated biology and biomarker-driven strategies to develop restorative treatments for people affected by central nervous system (CNS) disorders, today announced that Kevin Finney, President and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference in New York on Tuesday, June 4, 2024.
About Autobahn Therapeutics
Autobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric and neurodegenerative clinical candidates leveraging its brain-targeting chemistry platform. Autobahn aims to unlock new therapeutic opportunities through precision tuning of CNS exposure, pursuing validated clinical and biologic targets, and guiding development with biomarkers. The company’s pipeline is led by ABX-002, a thyroid hormone receptor beta (TRβ) agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder depression. Autobahn Therapeutics is based in San Diego. For more information, visit www.autobahntx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529594525/en/
Source: Autobahn Therapeutics
View this news release online at:
http://www.businesswire.com/news/home/20240529594525/en
